Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Constellation Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CNST is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: CNST's weekly volatility has increased from 14% to 19% over the past year.
7 Day Return
1 Year Return
Return vs Industry: CNST underperformed the US Biotechs industry which returned 20.7% over the past year.
Return vs Market: CNST underperformed the US Market which returned 42.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Constellation Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StRead This Before Buying Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) Shares
2 months ago | Simply Wall StWe're Hopeful That Constellation Pharmaceuticals (NASDAQ:CNST) Will Use Its Cash Wisely
11 months ago | Simply Wall StWhat Type Of Shareholder Owns Constellation Pharmaceuticals, Inc.'s (NASDAQ:CNST)?
Is Constellation Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CNST ($33.76) is trading below our estimate of fair value ($34.42)
Significantly Below Fair Value: CNST is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CNST is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CNST is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CNST's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CNST is overvalued based on its PB Ratio (4.3x) compared to the US Biotechs industry average (3.4x).
How is Constellation Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if CNST's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CNST's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CNST is forecast to be unprofitable in 3 years.
How has Constellation Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNST is currently unprofitable.
Growing Profit Margin: CNST is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CNST is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare CNST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: CNST has a negative Return on Equity (-37.36%), as it is currently unprofitable.
How is Constellation Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CNST's short term assets ($389.9M) exceed its short term liabilities ($25.3M).
Long Term Liabilities: CNST has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CNST is debt free.
Reducing Debt: CNST had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CNST has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CNST has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 33% each year.
What is Constellation Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CNST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CNST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNST's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CNST's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Jigar Raythatha has been the President, Chief Executive Officer and Director of Constellation Pharmaceuticals, Inc. since March 2017. Mr. Raythatha served as the Chief Business Officer at Jounce Therap...
CEO Compensation Analysis
Compensation vs Market: Jigar's total compensation ($USD5.86M) is above average for companies of similar size in the US market ($USD3.69M).
Compensation vs Earnings: Jigar's compensation has increased whilst the company is unprofitable.
Experienced Management: CNST's management team is considered experienced (3.9 years average tenure).
Experienced Board: CNST's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Constellation Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Constellation Pharmaceuticals, Inc.
- Ticker: CNST
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.622b
- Shares outstanding: 48.05m
- Website: https://www.constellationpharma.com
Number of Employees
- Constellation Pharmaceuticals, Inc.
- 215 First Street
- Suite 200
- United States
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 04:50|
|End of Day Share Price||2021/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.